Highlights
- Trajan to acquire Chromatography Research Supplies, Inc. (CRS), a leading global manufacturer of high-quality analytical consumables
- Provides Trajan with enhanced and extended production capabilities to service its growing gas chromatography business. Strengthens Trajan’s product portfolio particularly in the critical area of the gas chromatography inlet and sample introduction
- Expands global infrastructure footprint with the acquisition of manufacturing real estate assets in the US
- Follows three successful acquisitions and one strategic investment since listing on the ASX in June 2021
- Acquisition delivers FY22 forecast revenues of US$14.1 million (A$20.1 million[1]) and EBITDA of US$4.2 million (A$6.0 million[1])[2], and estimated annual synergies of ~A$1.3 million[7]
- Acquisition price of US$43.3 million (A$61.9 million[1]) implies ~9.5x FY22F EBITDA (pre synergies)[3]
- Expected to deliver FY23F earnings per share accretion of >31%[1],[4],[5],[6] (excluding the impact of synergies) or >42% (including 100% of the pro forma impact of identified corporate savings and product line synergies[7])
- Acquisition to be funded via a fully underwritten A$29.7 million institutional placement (Placement), A$20.0 million in acquisition debt financing through a facility with HSBC and $13.4 million from existing cash
- Investor webinar to be held at 10:30am (AEST) Friday 17th June 2022. Register via this link.
MELBOURNE, Australia, June 19, 2022 /PRNewswire/ — Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has today announced the signing of a binding share purchase agreement and a real estate purchase agreement to acquire 100% of Chromatography Research Supplies, Inc. (CRS), a leading global manufacturer of high-quality analytical consumables based in Kentucky, USA.
Having operated for over 25 years, CRS is a leading manufacturer of electronic and manual crimping tools, gas filters, ferrules, and injection port septa. Its products are used in analytical laboratories and various other industries worldwide and are known for their quality, ease of use and high levels of support.
The acquisition is highly complementary to Trajan’s existing product portfolio in the analytical workflow and consolidates Trajan’s current market leading position in gas chromatography sample introduction, supporting the quality of flow path connection and sealing functions with two leading product lines – septa and ferrules. CRS has been a long-term supplier of consumables to Trajan since Trajan’s acquisition of SGE Analytical in 2013.
In addition, the acquisition extends Trajan’s portfolio via CRS’ other product lines. Such product lines include tools that relate to sealing sample vials which are highly complementary to the Trajan Soltec business acquired in late 2018, and coating technologies that align strongly with Trajan’s automation businesses Axel Semrau and LEAP Pal Parts which were both acquired in late 2021.
CRS has a track record of strong financial performance, with accelerated growth expected in FY22F, adding FY22 forecasted revenue of US$14.1 million (A$20.1 million[8]) and forecast EBITDA of US$4.2 million (A$6.0 million[8])[9]. The acquisition price of US$43.3 million (A$61.9 million[8]) implies a ~9.5x EV/FY22F EBITDA[10] on a pre synergies basis.
Trajan has identified significant revenue and cost synergies as well as corporate savings realised from the date of acquisition and product line alignment, for total estimated annual synergy benefits of ~A$1.3 million[11], expected to ramp up within the first 2–3 years of ownership. Through the consolidation of current manufacturing facilities, Trajan can realise additional synergies over the medium to long term.
Stephen Tomisich, Chief Executive Officer and Managing Director of Trajan said: “The acquisition of CRS enhances multiple areas of our business and builds on our previous successful acquisitions to deliver comprehensive and best in class products in the analytical workflow.”
“Our market leadership in gas chromatography is enhanced with the addition of septa and ferrules components, as well as introducing a broader portfolio of products in other areas of the analytical workflow that build on our automation business.
As with our previous acquisitions, we have partnered with CRS for many years, understand their business, and know precisely where they fit within Trajan. The acquisition is earnings accretive and able to be rapidly integrated. Importantly, our acquisitions are building on capabilities to achieve our vision of personalised, preventative, data-based healthcare.”
Trajan has a proven framework to identify, acquire and integrate complementary businesses into its infrastructure. This framework involves a ‘founder friendly’ approach which is driven by deep industry relationships, targets solutions within the analytical workflow that have the potential to become industry best standard, is complementary to one or multiple business segments, and provides accretive and strategic opportunity to enhance shareholder value.
Utilising this framework Trajan has, over the past 11 years, built a strong track record of delivering acquisitive and organic growth. That process has accelerated since the Company’s IPO in June 2021, having acquired laboratory automation business Axel Semrau GmbH in November 2021, microsampling business Neoteryx LLC in December 2021, and LEAP PAL Parts and Consumables in December 2021, as well as entered a strategic investment in consumer health monitoring with Humankind Ventures Ltd (trading as Forth) in November 2021.
Acquisition consideration
Trajan is acquiring CRS for US$43.3 million (A$61.9 million[12]) through a share purchase agreement and a real estate purchase agreement, the latter being for the purchase of the land and building from which CRS operates in Kentucky, USA.
The Company will fund the acquisition of CRS via a fully underwritten A$29.7 million Placement to eligible institutional, sophisticated, and professional investors, an acquisition debt facility from HSBC of A$20.0 million and A$13.4 million from existing cash. Completion of Trajan’s acquisition of CRS is conditional on completion of the Placement and on Trajan satisfying customary conditions to drawdown under the HSBC acquisition financing facility.
The Placement is being issued at an offer price of $2.00 per new share (Offer Price), which represents a 11.1% discount to the last closing price of $2.25 on 16 June 2022.
The Placement will result in the issue of approximately 14.8 million new shares (New Shares), representing approximately 11.0% of Trajan’s existing shares on issue. The New Shares issued under the Placement will rank equally with existing Trajan shares at their date of issue.
Share Purchase Plan
Trajan will also offer eligible shareholders in Australia and New Zealand the opportunity to participate in a non-underwritten Share Purchase Plan (SPP). The SPP has a limit of $30,000 per eligible shareholder.
- New Shares under the SPP will be issued at $2.00 per share, being the same price as the Offer Price under the Placement.
- The SPP is being undertaken to raise up to $5.0 million[13].
- Trajan intends to use the proceeds of the SPP to support the Company’s growth objectives through further strategic acquisitions and organic growth opportunities.
- The SPP will open on Friday, 24 June 2022 and is expected to close at 5.00pm (AEST), Tuesday 12 July 2022.
- Further details relating to the SPP will be provided to eligible shareholders in Australia and New Zealand in due course.
Canaccord Genuity (Australia) Limited and Ord Minnett Limited are joint lead managers and underwriters to the Placement and DLA Piper is acting as legal advisor to Trajan.
Indicative timetable
The timetable below is indicative only and subject to change. The Company reserves the right to alter the dates at its discretion and without prior notice, subject to the ASX Listing Rules and Corporations Act 2001 (Cth).
|
Event
|
Date[14]
|
|
SPP Record Date
|
7:00pm, Thursday, 16 June 2022
|
|
Offer announcement
|
Friday, 17 June 2022
|
|
Placement bookbuild opens
|
Friday, 17 June 2022
|
|
Placement bookbuild closes (all jurisdictions)
|
2:00pm, Friday, 17 June 2022
|
|
Announce completion of Placement and trading halt lifted
|
Monday, 20 June 2022
|
|
Settlement of New Securities under the Placement (DvP)
|
Wednesday, 22 June 2022
|
|
Allotment and normal trading of New Securities issued under the Placement
|
Thursday, 23 June 2022
|
|
SPP opens
|
Friday, 24 June 2022
|
|
SPP closes
|
5:00pm, Tuesday, 12 July 2022
|
|
SPP results announced to the ASX
|
Friday, 15 July 2022
|
|
SPP Securities issued
|
Tuesday, 19 July 2022
|
Authorised for ASX release by the Board of Trajan Group Holdings Limited.
|
[1] AUD/USD 0.70 based on assumed AUD/USD exchange rate
|
|
[2] CRS FY22F EBITDA includes a rent expense of US$228K
|
|
[3] EV / FY22F EBITDA multiple of 9.5x is based on an enterprise value of US$40.2 million (excluding the acquisition of freehold title to real estate owned by CSR for US$3.1 million) and an FY22F EBITDA of US$4.2 million converted to AUD at AUD/USD0.70
|
|
[4] Before one-off transaction and implementation costs
|
|
[5] Accretion assumes a pre-tax interest rate of 4%
|
|
[6] FY23F accretion assumes analyst consensus NPAT estimate of A$8.8m and CSR NPAT of A$4.7m (excluding corporate savings and product line synergies) and an effective tax rate of 20% for CSR based on Trajan management’s due diligence
|
|
[7] Refer to page 17 of the ASX Investor Presentation dated 17 June 2022
|
|
[8] AUD/USD 0.70 based on assumed AUD/USD exchange rate
|
|
[9] CRS FY22F EBITDA includes a rent expense of US$228K
|
|
[10] EV / FY22F EBITDA multiple of 9.5x is based on an enterprise value of US$40.2 million (excluding the acquisition of freehold title to real estate owned by CSR for US$3.1 million) and an FY22F EBITDA of US$4.2 million converted to AUD at AUD/USD0.70
|
|
[11] Refer to page 17 of the ASX Investor Presentation dated 17 June 2022
|
|
[12] AUD/USD 0.70 based on assumed AUD/USD exchange rate at time of completion
|
|
[13] The Company reserves its discretion regarding the final amount to be raised under the SPP
|
|
[14] The above timetable is indicative only and is subject to change without notice. All dates and times are Australian Eastern Standard Time (AEST).
|
About Trajan
Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.
Trajan is a global organisation of 600 people with seven manufacturing sites across the US, Australia, Europe, and Malaysia, and operations in Australia, the US, Asia, and Europe.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trajan-to-acquire-leading-chromatography-consumables-and-tools-business-building-critical-mass-in-the-gas-chromatography-portfolio-301570332.html
View original content:
View original content:
View original content:
View original content to download multimedia:
